** Shares of Pennsylvania-based medtech firm Neuronetics STIM.O rise 8.2% to $4.61
** Company forecasts 2025 revenue between $145 million and $155 million, above analysts' estimate of $93.55 million, according to data compiled by LSEG
** Company, which offers its NeuroStar device to treat major depressive disorder (MDD), posts Q4 revenue of $22.49 million, beating analysts' estimates of $19.63 million
** In the last 12 months, STIM has fallen 41.5%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.